With allergy misdiagnosis affecting nearly half of Europeans, Lithuania’s Self.co secures €2.56 million to make testing accessible

Self.co, a Vilnius-based digital health company helping users understand and manage allergies and food intolerances, has raised €2.56 million in a combined grant and venture funding round to support the expansion into new markets and further development of Self.co’s proprietary testing technology and long-term management tools.

The funding round of €1.2 million was led by Iron Wolf Capital, with participation from Coinvest, NGL Ventures, and several angel investors. Self.co received the €1.36 million grant from Innovation Agency Lithuania to improve its testing technology.

Tautvydas Gylys, co-founder and CEO of Self.co, said: “Millions of people live with allergy-like symptoms but without a real understanding of what’s causing them or what to do about it. We’ve taken advanced diagnostic technology and built a simple test system that gives anyone clear, medically valid answers without the high cost or long wait.

This raise for Self.co fits into a broader European trend of continued investment in diagnostics and digital health during 2025.

EU-Startups coverage shows a steady flow of comparable rounds – for instance, CGC Genomics (Switzerland) secured €1.7 million to scale its regulated GenAI platform for genomic analysis, while Cytely (Sweden) raised €3 million to expand its smart-microscopy diagnostic tools. In Germany, roclub obtained €10 million to advance AI-powered remote operations in medical technology.

Together, these deals underline a clear 2025 pattern of investors supporting digital and AI-enabled diagnostic platforms that reduce testing costs or increase analytical speed.

Self.co’s model – integrating molecular allergy testing with digital symptom management – reflects this shift towards accessible, data-driven care solutions.

While most funding activity remains concentrated in countries such as Switzerland, Germany, and Sweden, Self.co adds Baltic representation to this expanding European HealthTech landscape.

“Now the funding will help us bring our product to new markets like the UK, Ireland, Austria, and Germany, and deepen ongoing collaboration with healthcare systems in Poland and Lithuania,” added Gylys.

Founded in 2015 by Gintautas Gylys, Self.co is a digital health and diagnostics company helping people understand allergy-like symptoms through molecular testing and expert guidance.

The company controls its entire testing process, from technology development to lab analysis. Its proprietary microarray tests analyse 98 allergens and 220 food sensitivities from a simple blood sample taken at home or in partner clinics.

Beyond testing, Self.co provides users with personalised avoidance plans and, when needed, supplements or treatments, empowering thousands to properly diagnose allergy-like symptoms and live healthier lives.

Kasparas Jurgelionis, Managing Partner at Iron Wolf Capital, says: “As DeepTech investors, we back technologies with the potential to transform established industries – and that’s exactly what Self.co is doing in allergy diagnostics and care. This is a large, fast-growing market still underserved by current solutions.”

Allergies and intolerances affect between 30 and 40 percent of the global population, a number expected to climb to nearly 4 billion people by mid-century (European Academy of Allergy and Clinical Immunology). Despite this prevalence, the company argues that diagnosis remains one of healthcare’s biggest blind spots.

Around 45% of individuals with allergy-like symptoms in the EU are either misdiagnosed or never diagnosed at all (EAACI). Many of these people confuse allergies with other immune or digestive conditions such as intolerances or sensitivities, leading to years of uncertainty and ineffective treatment.

The problem is compounded by long waiting times, often more than six months for specialist testing in public systems, and prohibitive costs. Layers of intermediaries, low test throughput, and provider costs reportedly create markups on a single molecular allergy test of between €200 and €400. This puts accurate diagnoses prohibitively out of reach for millions.

As a result, people continue to live with fatigue, skin rashes, or digestive symptoms without real answers, while healthcare systems absorb billions in avoidable costs each year.

Self.co’s digital service looks to tackle this with a holistic and scientific approach. Its core products are two proprietary microarray tests that analyse 98 allergens and 220 food sensitivities using a simple blood sample that people can take at home or in a partner clinic.

Once evaluated by professional lab technicians, Self.co provides users with a detailed avoidance plan and connects them with supplements and treatments as needed through partnerships with local healthcare providers.

By controlling the entire testing process, from technology development to lab analysis, and eliminating intermediaries, Self.co offers the same laboratory-grade testing for €69–€99, a fraction of the traditional €200–€400 cost.

“Tautvydas and the team combine exceptional industry insight with strong execution, giving them a rare founder-market fit. Self.co’s platform addresses long-standing pain points for patients and clinicians, positioning the company to redefine allergy care globally. We’re proud to lead this round and support their mission to deliver meaningful healthcare innovation at scale,” adds Jurgelionis.

Self.co’s testing technology, developed by allergists and lab specialists, claims to achieve molecular-level precision through microarray innovation. Advanced calibration methods tailor measurements for each allergen, reportedly ensuring accuracy even at very low levels, while sensitive fluorescence detection identifies the smallest immune responses. AI then merges clinical data and expert review to deliver a personalised, actionable report.

Self.co will use the new funding to develop a comprehensive digital health platform that serves as an entry point for people experiencing allergy-like symptoms. The platform will include advanced symptom questionnaires to pinpoint conditions, expanded test offerings, and better integration with traditional healthcare systems.

Self.co says they are aiming to become the go-to digital health platform for top-to-bottom allergy care in Europe by 2030.

The post With allergy misdiagnosis affecting nearly half of Europeans, Lithuania’s Self.co secures €2.56 million to make testing accessible appeared first on EU-Startups.